Compare Archean Chemical with Similar Stocks
Dashboard
Poor long term growth as Net Sales has grown by an annual rate of -6.76% and Operating profit at -23.20% over the last 5 years
With a fall in Operating Profit of -20.1%, the company declared Very Negative results in Sep 25
With ROE of 9, it has a Very Expensive valuation with a 3.7 Price to Book Value
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Specialty Chemicals
INR 7,185 Cr (Small Cap)
41.00
39
0.53%
0.05
8.97%
3.66
Total Returns (Price + Dividend) 
Latest dividend: 3 per share ex-dividend date: May-26-2025
Risk Adjusted Returns v/s 
Returns Beta
News

Archean Chemical Industries Ltd Upgraded to Sell Amid Mixed Financial and Valuation Signals
Archean Chemical Industries Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 27 Jan 2026, reflecting a nuanced reassessment of its quality, valuation, financial trends, and technical outlook. Despite ongoing challenges in profitability and sales growth, certain operational strengths and valuation adjustments have prompted this recalibration by MarketsMOJO.
Read full news article
Archean Chemical Industries Ltd is Rated Strong Sell
Archean Chemical Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 January 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 24 January 2026, providing investors with the latest view on the company’s position.
Read full news article
Archean Chemical Industries Ltd Faces Bearish Momentum Amid Technical Deterioration
Archean Chemical Industries Ltd has experienced a notable shift in price momentum, with technical indicators signalling a bearish trend. Despite a recent downgrade to a Strong Sell rating, the stock’s price action and key metrics reveal a complex picture amid broader market challenges.
Read full news article Announcements 
Corporate Actions 
04 Feb 2026
Archean Chemical Industries Ltd has declared 150% dividend, ex-date: 26 May 25
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Promoters
13.918
Held by 12 Schemes (16.97%)
Held by 80 FIIs (11.08%)
Chemikas Speciality Llp (30.53%)
Sbi Small Cap Fund (6.88%)
8.13%
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
QoQ Growth in quarter ended Sep 2025 is -20.24% vs -15.40% in Jun 2025
QoQ Growth in quarter ended Sep 2025 is -27.62% vs -24.93% in Jun 2025
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 15.97% vs -28.48% in Sep 2024
Growth in half year ended Sep 2025 is 14.25% vs -62.07% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'24
YoY Growth in nine months ended Dec 2024 is -33.53% vs -1.18% in Dec 2023
YoY Growth in nine months ended Dec 2024 is -58.45% vs 6.23% in Dec 2023
Annual Results Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is -21.73% vs -7.70% in Mar 2024
YoY Growth in year ended Mar 2025 is -49.17% vs -16.62% in Mar 2024






